Ovarian function improving composition and pharmaceuticals, food and beverages, and feed containing the same.

Abstract

To provide an ovarian function improving composition that uses safe and side-effect-free materials, is relatively easy to manufacture, and can be administered orally, as well as pharmaceuticals, food and beverages, and animal feed containing the same. [Solution] The ovarian function improving composition contains a processed product of Agaricus.

Description

Technical Field

[0001] The present invention relates to an ovarian function improving composition, and a medicine, food and drink, and feed containing the same.

Background Art

[0002] There is a close relationship between a woman's age and pregnancy, and the pregnancy rate tends to decrease with aging. One of the major reasons is the decline in ovarian function (such as a decrease in the number and quality of eggs in the ovary). In recent years, the age at which women get married has been increasing year by year, and it is said that the number of women who have difficulty getting pregnant due to the decline in ovarian function caused by aging is increasing even without an obvious cause of infertility.

[0003] Regarding the decrease in the pregnancy rate due to the decline in ovarian function, it is difficult to achieve sufficient results by reproductive medicine such as in vitro fertilization, so means for suppressing the decline in ovarian function are required.

[0004] In Patent Document 1, a preparation consisting of pterostilbene is described as an agent for preventing or improving the decline in ovarian function. Further, in Patent Document 2, an ovarian function improving agent obtained by culturing stem cells isolated from menstrual blood and suspending them in an injection solution is described.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0006] However, the pterostilbene described in Patent Document 1 is not clear about the effects of long-term intake in humans, and there are many unclear points regarding safety, including side effects and interactions with other drugs. Furthermore, the ovarian function improving agent described in Patent Document 2 has the problem that obtaining menstrual blood stem cells is not always easy, and that administration by injection is required, which places a significant physical burden on the patient.

[0007] This invention has been made in view of the above circumstances, and aims to provide an ovarian function improving composition that uses safe and side-effect-free materials, is relatively easy to manufacture, and can be administered orally, as well as pharmaceuticals, food and beverages, and animal feed containing the same. [Means for solving the problem]

[0008] To solve the above problems, the following ovarian function improving compositions and pharmaceuticals, food and beverages, and animal feeds containing the same are provided. [1] Contains processed Agaricus, A composition for improving ovarian function. [2] The ovarian function improving composition according to [1], wherein the Agaricus is an Agaricus fruiting body. [3] The ovarian function improving composition according to [1] or [2], wherein the Agaricus is King·Agaricus 21 strain (accession number: FERM P-17695). [4] An ovarian function improving composition according to any of the above [1] to [3], wherein the processed product is a dried product. [5] An ovarian function improving composition according to any of the above [1] to [4], which improves the decline in ovarian function due to aging. [6] A pharmaceutical agent for improving ovarian function, comprising any of the ovarian function improving compositions described in [1] to [4] above. [7] Food and beverage for improving ovarian function, comprising any of the ovarian function improving compositions described in [1] to [4] above. [8] A feed for improving ovarian function, comprising any of the ovarian function improving compositions described in [1] to [4] above. [Effects of the Invention]

[0009] The ovarian function improving composition of the present invention, and the pharmaceuticals, food products, and feeds containing the same, are made using safe and side-effect-free materials, are relatively easy to manufacture, and can improve ovarian function (suppress the decline in ovarian function) when administered orally or ingested. [Brief explanation of the drawing]

[0010] [Figure 1] These images show the condition of the ovaries of Drosophila melanogaster ferns 7 and 35 days after administration of dried Agaricus fruiting bodies (KAOD and KAID). [Figure 2] This figure shows the changes in ovarian size 7 and 35 days after administration of dried Agaricus fruiting bodies (KAOD and KAID) to Drosophila melanogaster. [Figure 3] This figure shows the change in egg-laying numbers 7 and 35 days after administration of dried Agaricus fruiting bodies (KAOD and KAID) to Drosophila melanogaster. [Modes for carrying out the invention]

[0011] The inventors of this invention have discovered a novel finding that Agaricus (preferably the fruiting body of Agaricus brasiliensis) has an effect of improving ovarian function (an effect of suppressing the decline of ovarian function), and have completed the present invention.

[0012] An embodiment of the ovarian function improving composition of the present invention will be described below.

[0013] The "effect of improving ovarian function" in the ovarian function improving composition of the present invention includes, for example, suppression of the decrease in the number of ovulated eggs and an increase in the number of ovulated eggs, suppression of the decrease in the number of germ stem cells and an increase in the number of germ stem cells, suppression of the decrease in the implantation rate of fertilized eggs and an increase in the implantation rate of fertilized eggs, suppression of the decrease in the live birth rate and an increase in the live birth rate, suppression of the increase in the miscarriage rate and a decrease in the miscarriage rate, and an increase in the success rate of artificial insemination, in vitro fertilization, and intracytoplasmic sperm injection.

[0014] In addition, the ovarian function improving composition of the present invention typically improves the decline in ovarian function due to aging. Furthermore, since a decline in ovarian function also affects the external attractiveness as a woman, such as skin gloss, the ovarian function improving composition of the present invention contributes to the beauty of women through the improvement of ovarian function.

[0015] The ovarian function improving composition of the present invention contains a processed product of Agaricus (fruit body and / or mycelium). Agaricus has been conventionally eaten as food and is a safe material with no side effects.

[0016] The form of Agaricus is preferably the fruit body. Examples of Agaricus fruit bodies (fruit bodies such as Agaricus blazei Murill, Agaricus brasiliensis, Agaricus subrufescens) include, for example, wild fruit bodies and fruit bodies obtained by cultivation.

[0017] Among them, it is preferable that Agaricus is King Agaricus 21 with the deposit number FERM P-17695 (date of deposit: January 13, 2000; date of re-deposit: July 1, 2016) deposited with the National Institute of Technology and Evaluation. When the ovarian function improving composition of the present invention contains a processed product of King Agaricus 21 (FERM P-17695), an excellent ovarian function improving effect is achieved as compared with Agaricus of other strains. Among them, the Agaricus fruit body is preferably the fruit body of King Agaricus 21 cultivated in the open field.

[0018] In addition, the processed product of Agaricus may be various processed products obtained by physically, chemically or biologically processing Agaricus (preferably the fruit body). Since the processed product of Agaricus may be a processed product by a conventionally known method, the production of the ovarian function improving composition of the present invention is relatively easy.

[0019] Specifically, examples of the physical and chemical processed products include processed products obtained by drying such as sun drying, air drying, freeze drying, etc., freeze-dried products, and pulverized products obtained by a blender, a homogenizer, a ball mill, etc. The pulverized product may have a crushed cell wall. Examples of the biological treatment method include a fermentation method. Among them, the fruiting body is preferably in the form of a processed product obtained by drying or freeze drying.

[0020] In addition, the processed product of Agaricus includes extracts obtained by various extraction methods from the fruiting body and / or mycelium as long as it contains the active ingredient. Examples of the extraction method include various solvent extractions, supercritical fluid extraction, etc. The extracts include those containing the low molecular weight active ingredient of Agaricus. The extracts may be treated by various solid-liquid separation methods such as sedimentation separation, cake filtration, clarification filtration, centrifugal filtration, centrifugal sedimentation, pressing separation, filter press, etc., various concentration methods, various drying methods, formulation methods such as granulation or powdering, and various purification methods.

[0021] Furthermore, the processed product of Agaricus may be added to a solvent such as water to form a liquid composition for improving ovarian function.

[0022] The method for producing the composition for improving ovarian function of the present invention includes a step of blending the processed product of Agaricus, and may include various other conventionally known steps.

[0023] The composition for improving ovarian function of the present invention can be in the form of a medicine, food or drink, or feed (or feed additive), and can be orally administered or ingested by mammals. That is, the medicine, food or drink, and feed of the present invention contain the above-described composition for improving ovarian function.

[0024] (Medicine) The medicine for improving ovarian function of the present invention is a medicine for improving ovarian function decline, and includes the above-described composition for improving ovarian function of the present invention.

[0025] The pharmaceutical product of the present invention may use the ovarian function improving composition of the present invention as an active ingredient as is, or it may be formulated by adding pharmaceutically acceptable ingredients.

[0026] The pharmaceutical product of the present invention is preferably in a dosage form for oral administration, but may also be in a dosage form for parenteral administration. Examples of orally administered dosage forms include powders, granules, tablets, capsules, elixirs, and microcapsules. Examples of parenteral dosage forms include injections, intravenous infusions, ointments, inhalants, suppositories, and topical preparations.

[0027] The pharmaceutical product of the present invention may contain a pharmaceutically acceptable carrier. Examples of such carriers include known excipients, disintegrants, binders, lubricants, surfactants, buffers, solubilizers, stabilizers, isotonic agents, suspending agents, emulsifiers, solvents, thickeners, mucolytic agents, wetting agents, and preservatives.

[0028] The pharmaceutical product of the present invention may further contain additives. Examples of additives include lubricants such as magnesium stearate; sweeteners such as sucrose, lactose, and saccharin; flavoring agents such as peppermint and red ginger oil; stabilizers such as benzyl alcohol and phenol; buffering agents such as phosphates and sodium acetate; solubilizers such as benzyl benzoate and benzyl alcohol; antioxidants; and preservatives.

[0029] The pharmaceutical product of the present invention can be formulated by appropriately combining the carriers and additives described above and mixing them in a unit dose form generally accepted for pharmaceutical production.

[0030] The dosage of the pharmaceutical agent of the present invention varies depending on the patient's weight, age, symptoms, and method of administration, but a person skilled in the art can appropriately select an appropriate dosage. The dosage of the ovarian function improving composition of the present invention when administered to humans varies depending on the symptoms, the patient's age, sex, weight, sensitivity differences, administration interval, type of active ingredient, and type of formulation, and is not particularly limited, but for example, when administered orally, an amount selected from 0.1 mg / kg to 100 g / kg per day can be administered or ingested in one or multiple doses (for example, 2 to 5 times, preferably 2 to 3 times).

[0031] Furthermore, the duration of administration or intake of the pharmaceutical product of the present invention is not limited, but for example, the pharmaceutical product of the present invention can be continuously administered orally for a period of one week or more, two weeks or more, one month or more, two months or more, six months or more, one year or more, or longer, according to the above-mentioned dosage and administration instructions.

[0032] The target animals for administration of the pharmaceutical product of the present invention include mammals, including humans (for example, livestock such as cattle and pigs, racehorses, pets such as dogs and cats, chickens, etc.).

[0033] (food and drink) The food and beverages for improving ovarian function of the present invention are food and beverages for improving ovarian dysfunction and include the ovarian function improving composition of the present invention described above.

[0034] Examples of food and beverages include health foods and beverages in the form of tablets, chewable tablets, powders, capsules, granules, and drinks (supplements, nutritional supplements, health foods, nutritional adjustment foods, etc.), protein-containing foods and beverages, soft drinks, tea drinks, jelly drinks, sports drinks, coffee drinks, carbonated drinks, vegetable drinks, fruit juice drinks, fermented vegetable drinks, fermented fruit juice drinks, fermented milk drinks (yogurt, etc.), lactic acid bacteria drinks, milk drinks, powdered drinks, cocoa drinks, alcoholic beverages, broth, confectionery, and jelly. In particular, it is preferable that the food and beverages be in the form of health functional foods (foods for specified health uses, nutrient function foods, foods with functional claims) or health foods.

[0035] Furthermore, the "food and beverage" of the present invention may contain ingredients commonly used in the field of food engineering. Specifically, for example, various oils and fats (e.g., vegetable oils such as soybean oil, corn oil, safflower oil, olive oil, etc., and animal oils such as beef tallow and sardine oil), herbal medicines (e.g., royal jelly, ginseng, etc.), amino acids (e.g., glutamine, cysteine, leucine, arginine, etc.), polyhydric alcohols (e.g., ethylene glycol, polyethylene glycol, propylene glycol, glycerin, sugar alcohols, for example, sorbitol, erythritol, xylitol, maltitol, mannitol, etc.), natural polymers (e.g., gum arabic, agar, water-soluble corn fiber, gelatin, xanthan gum, etc.) Examples of ingredients include corn gum, casein, gluten or gluten hydrolysate, lecithin, starch, dextrin, etc., vitamins (e.g., vitamin C, B vitamins, etc.), minerals (e.g., calcium, magnesium, zinc, iron, etc.), dietary fiber (e.g., mannan, pectin, hemicellulose, etc.), surfactants (e.g., glycerin fatty acid ester, sorbitan fatty acid ester, etc.), purified water, diluents, stabilizers, isotonic agents, pH adjusters, buffers, humectants, solubilizers, suspending agents, colorants, flavoring agents, odorants, fragrances, antioxidants, sweeteners, flavor components, and acidulants.

[0036] The amount of food and beverages consumed will vary depending on the patient's weight, age, symptoms, etc., but a person skilled in the art can appropriately select a suitable dosage. Specifically, the dosage and duration of intake may be the same as those for the pharmaceutical product of the present invention.

[0037] (feed) The ovarian function-improving composition of the present invention can be used not only as food and beverages for humans, but also as feed (or feed additive) for animals such as livestock like cattle and pigs, racehorses, pets like dogs and cats, and chickens. The ovarian function-improving feed of the present invention can be formulated with processed Agaricus blazei along with various conventionally known components.

[0038] The dosage or intake of the pharmaceutical and food products of the present invention can be adjusted as appropriate, taking into consideration the age and weight of the target individual, the number of administrations or intakes, etc.

[0039] The ovarian function improving composition, pharmaceuticals, food and beverages, and feed for improving ovarian function of the present invention are not limited to the embodiments described above. Furthermore, since the ovarian function improving composition, pharmaceuticals, food and beverages, and feed of the present invention contain processed Agaricus products, conventionally known medicinal effects such as strengthening and improving the liver, heart, and gastrointestinal tract, stabilizing blood pressure and blood sugar levels, relieving lower back pain and stiff shoulders, improving hair loss and graying hair, enhancing immunity, antitumor effects, reducing side effects of anticancer drugs, promoting wound healing, and improving symptoms of menopause can also be achieved.

[0040] The method for producing the ovarian function improving composition of the present invention includes the step of incorporating a processed product of Agaricus grown in open field under the conditions of the following examples. [Examples]

[0041] The ovarian function improving composition of the present invention will be described in detail below with reference to examples, but the ovarian function improving composition of the present invention is not limited in any way to the following examples.

[0042] <1> Dried Agaricus fruiting body As the dried Agaricus fruiting body (dried fruiting body powder), we used Agaricus brasiliensis KA21 strain, which was cultivated outdoors in Brazil. This Agaricus (King Agaricus) is deposited with the National Institute of Technology and Evaluation (Accession number FERM P-17695 King·Agaricus 21). Hereafter, this outdoors-cultivated Agaricus brasiliensis KA21 strain (=KA21 strain) may be referred to as "KAOD". An example of how to cultivate KAOD is as follows: 1) Mix the starter culture into compost and allow the fungi to grow. 2) Plant the grown fungi and compost in the ridges of the field. 3) Allow the fungi to grow for 3-4 weeks in a natural environment, exposed to sunlight. 4) Harvest after the fruiting bodies have grown.

[0043] Furthermore, as a greenhouse-grown Agaricus, we used dried fruiting bodies of the Agaricus brasiliensis KA21 strain, which was grown in a greenhouse in Brazil. Hereafter, this greenhouse-grown Agaricus may be referred to as "KAID".

[0044] <2> Changes in ovarian size due to administration of dried Agaricus fruiting bodies Female Drosophila melanogaster were fed a diet containing 5% each of dried Agaricus fruiting bodies (KAOD and KAID) for 35 days, and changes in ovarian size were observed by microscopic imaging of the ovaries. Figure 1 shows images of the ovaries 7 and 35 days after ingestion of dried Agaricus fruiting bodies (KAOD and KAID). Figure 2 shows the quantitative results of ovarian size 7 and 35 days after administration of dried Agaricus fruiting bodies (KAOD and KAID) to Drosophila melanogaster.

[0045] As shown in Figures 1 and 2, it was confirmed that KAOD and KAID intake tend to increase ovarian size (suppressing age-related decline in ovarian size).

[0046] <3> Changes in egg count due to administration of dried Agaricus fruiting bodies Female Drosophila melanogaster were fed a diet containing 5% each of dried Agaricus fruiting bodies (KAOD and KAID) for 35 days, and the number of eggs laid within a 24-hour period was measured for each individual. Figure 3 shows the change in the number of eggs laid 7 and 35 days after ingestion of dried Agaricus fruiting bodies (KAOD and KAID).

[0047] As shown in Figure 3, it was confirmed that administration of KAOD significantly increased the number of eggs laid in older individuals (suppressing the age-related decline in egg production).

[0048] Based on these results, it was confirmed that administering a processed Agaricus fruiting body product improves ovarian function.

Claims

1. Contains processed Agaricus mushrooms. A composition for improving ovarian function.

2. The aforementioned Agaricus is an Agaricus fruiting body. The ovarian function improving composition according to claim 1.

3. The aforementioned Agaricus is King Agaricus strain 21 (accession number: FERM P-17695). The ovarian function improving composition according to claim 1.

4. The aforementioned processed product is a dried processed product. The ovarian function improving composition according to claim 1.

5. To improve age-related decline in ovarian function, The ovarian function improving composition according to claim 1.

6. A composition containing the ovarian function improving composition of claim 1, A medicine for improving ovarian function.

7. A composition containing the ovarian function improving composition of claim 1, Food and beverages for improving ovarian function.

8. A composition containing the ovarian function improving composition of claim 1, Feed for improving ovarian function.

Images